GPNMB Human, Sf9
Sf9, Baculovirus cells.
Greater than 90.0% as determined by SDS-PAGE.
Description
GPNMB Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 462 amino acids (22-474a.a.) and having a molecular mass of 51.8kDa. GPNMB is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Sf9, Baculovirus cells.
ADPAKRFHDV LGNERPSAYM REHNQLNGWS SDENDWNEKL YPVWKRGDMR WKNSWKGGRV QAVLTSDSPA LVGSNITFAV NLIFPRCQKE DANGNIVYEK NCRNEAGLSA DPYVYNWTAW SEDSDGENGT GQSHHNVFPD GKPFPHHPGW RRWNFIYVFH TLGQYFQKLG RCSVRVSVNT ANVTLGPQLM EVTVYRRHGR AYVPIAQVKD VYVVTDQIPV FVTMFQKNDR NSSDETFLKD LPIMFDVLIH DPSHFLNYST INYKWSFGDN TGLFVSTNHT VNHTYVLNGT FSLNLTVKAA APGPCPPPPP PPRPSKPTPS LGPAGDNPLE LSRIPDENCQ INRYGHFQAT ITIVEGILEV NIIQMTDVLM PVPWPESSLI DFVVTCQGSI PTEVCTIISD PTCEITQNTV CSPVDVDEMC LLTVRRTFNG SGTYCVNLTL GDDTSLALTS TLISVPHHHH HH.
Product Science Overview
Glycoprotein non-metastatic melanoma protein B (GPNMB), also known as osteoactivin, is a type-I transmembrane glycoprotein. It was initially identified in a melanoma cell line and has since been found to play various roles in different biological processes, including bone mineralization, immune response, and neuroprotection . The recombinant form of this protein, produced in Sf9 insect cells, is used in various research applications to study its functions and potential therapeutic uses.
GPNMB is composed of an extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. The extracellular domain contains several glycosylation sites, which are crucial for its stability and function. GPNMB can be cleaved by extracellular proteases such as ADAM10, releasing a soluble fragment that can act as a signaling molecule .
- Bone Mineralization: GPNMB has been shown to stimulate osteoblast differentiation, thereby promoting bone mineral deposition .
- Immune Response: GPNMB is involved in the regulation of immune responses. It is expressed in activated microglia and astrocytes, where it plays a role in modulating inflammatory responses .
- Neuroprotection: GPNMB has demonstrated neuroprotective properties in various models of neurodegenerative diseases. For instance, it has been shown to attenuate astrocyte inflammatory responses through the CD44 receptor, reducing the production of inflammatory cytokines and reactive oxygen species .
GPNMB has been implicated in several diseases, including cancer, neurodegenerative disorders, and inflammatory conditions:
- Cancer: GPNMB is overexpressed in various cancers, including melanoma, breast cancer, and glioblastoma. Its expression is associated with tumor progression and metastasis.
- Neurodegenerative Diseases: Elevated levels of GPNMB have been observed in the brains of patients with Alzheimer’s disease and Parkinson’s disease. It is believed to play a role in the neuroinflammatory response associated with these conditions .
- Inflammatory Conditions: GPNMB is involved in the regulation of inflammatory responses in diseases such as rheumatoid arthritis and multiple sclerosis.
The recombinant form of GPNMB, produced in Sf9 insect cells, is widely used in research to study its structure, function, and potential therapeutic applications. Researchers use this recombinant protein to investigate its role in various biological processes and to develop potential treatments for diseases associated with GPNMB dysregulation.
